

## **SAKK / AMGEN Research Grant 2017 – Regulations**

### **1. Research grant**

SAKK and AMGEN are highly interested in innovative and practice relevant oncology research that improves patient's lives. With that aspiration, SAKK conducts important clinical studies and AMGEN develops innovative drugs to manage serious illnesses.

SAKK and AMGEN would like to advance translational cancer research in Switzerland and award the SAKK / AMGEN research grant every two years for outstanding and novel translational cancer research.

The grant is endowed with 50'000 CHF. The grant should contribute to an independent research project and cover a substantial scientific part of the project. The submitted research project should not be a small translational part of a large clinical trial. The prize winner will provide a written summary of his/her research project within two years.

### **2. Applicants**

Researcher or a research team independent of their nationality and age, working at a Swiss hospital or institution can apply for the SAKK / AMGEN research grant.

### **3. Research projects**

Eligibility of submitted research projects:

- Translational cancer research based
- Research areas: oncology and hematology
- The planned research project will predominantly be performed in Switzerland

Already published work is not taken into consideration for the SAKK / AMGEN research grant.

### **4. Jury**

An independent jury will evaluate the anonymous proposals. The jury consists of the SAKK president, three reviewers of different Swiss institutions selected by the SAKK president and a representative of AMGEN Switzerland AG. The jury will be chaired by the president of the SAKK.

All proposals are evaluated by all jury members during two review rounds. If additional scientific expertise is needed the SAKK president can request written evaluations from additional reviewers.

The jury will elect the winning research project by consensus voting based on novelty, clinical relevance and feasibility of the project. The SAKK president will inform the prize winner and the other applicants at least 1 month prior to the SAKK semi-annual meeting in November.

## 5. Submission of application

All of the following documents must be submitted:

- Completed application form
- Anonymous description of the research project in English (max. 3 pages, comprising a short summary (novelty, relevance) and a project overview incl. work plan with timelines (feasibility), budget estimation and references)
- CV of applicant (team lead)

Deadline for the submission of proposals is 31 August 2017. Submissions have to be sent electronically to Amgen Switzerland AG ([researchgrant.ch@amgen.com](mailto:researchgrant.ch@amgen.com)).

Application forms can be ordered from Amgen Switzerland AG, SAKK / AMGEN Research Grant, Dammstrasse 21 6, P.O. Box 1459, 6301 Zug, via e-Mail ([researchgrant.ch@amgen.com](mailto:researchgrant.ch@amgen.com)) or can be downloaded from [www.amgen.ch](http://www.amgen.ch), SAKK / AMGEN Research grant.

## 6. Prize award ceremony

The grant will be awarded at the SAKK semi-annual meeting in November and published in the Swiss Krebsbulletin. The prize winner will present the research project and the previous prize winner will present the outcome of his/her research also during the SAKK semi-annual meeting in November.

Bern, June 2017

**Schweizerische Arbeitsgemeinschaft  
für Klinische Krebsforschung (SAKK)**

Prof. Dr. med. Roger von Moos  
President

**Amgen Switzerland AG**

Christian Merkle, PhD  
Therapeutic Area Head, Oncology